Profound Medical Corp. announced that the results of their Phase I Clinical Trial have been accepted for publication in European Urology. In the paper, entitled 'Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase I Clinical Trial”, Prof. Joseph L. Chin, M.D. and his team from Western University, London Health Sciences Centre, and investigators Dr. Sasha Pahernik (University Hospital Heidelberg), Dr. James Relle (William Beaumont Hospital), and Professor Heinz-Peter Schlemmer (DKFZ) report on the single arm prospective Phase 1 study.

MRI-guided transurethral ultrasound ablation (TULSA) was used to heat and ablate prostate tissue in 30 men with localized prostate cancer. The procedure was delivered using Profound Medical's TULSA-PROTM, with the objective to determine its clinical safety and feasibility for whole-gland prostate ablation in the primary treatment setting of patients with localized prostate cancer. The 12-month data shows that the TULSA-PRO is spatially accurate and precise to ablate prostate tissue, both malignant and benign, while providing a favourable safely profile and a low rate of erectile dysfunction.